Management of STEMI in low- and middle-income countries

Global Heart

Volumn 9, Issue 4, 2014, Pages 469-510

  Baliga, Ragavendra R ^a   Bahl, Vinay K ^b   Alexander, Thomas ^c   Mullasari, Ajit ^d   Manga, Pravin ^e   Dec, G William ^f   Narula, Jagat ^g  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^c KOVAI MEDICAL CENTER AND HOSPITAL   (India)

^d MADRAS MEDICAL MISSION HOSPITAL   (India)

^e UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ANALGESIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCERYL TRINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; THIENOPYRIDINE DERIVATIVE; ANTICOAGULANT AGENT; PURINERGIC P2Y RECEPTOR ANTAGONIST;

ACUTE HEART INFARCTION; ANALGESIA; ANGIOCARDIOGRAPHY; ANTICOAGULANT THERAPY; CARDIOGENIC SHOCK; CARDIOVASCULAR MORTALITY; CLINICAL EXAMINATION; CORONARY REPERFUSION; DEVELOPING COUNTRY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; FIBRINOLYSIS; HEART FAILURE; HEART MUSCLE OXYGEN CONSUMPTION; HOSPITAL MANAGEMENT; HUMAN; OXYGEN THERAPY; PERCUTANEOUS CORONARY INTERVENTION; PHYSICAL EXAMINATION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SECONDARY PREVENTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; BLOOD; ECONOMICS; ELECTROCARDIOGRAPHY; HEART MUSCLE REPERFUSION; MYOCARDIAL INFARCTION; POVERTY; PROCEDURES; SOCIAL CLASS;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTICOAGULANTS; BIOLOGICAL MARKERS; DEVELOPING COUNTRIES; ELECTROCARDIOGRAPHY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; PLATELET AGGREGATION INHIBITORS; POVERTY; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RISK ASSESSMENT; SOCIAL CLASS;

EID: 84920775520     PISSN: 22118160     EISSN: 22118179     Source Type: Journal    
DOI: 10.1016/j.gheart.2014.11.001     Document Type: Article

References (154)

1. Gibson CM. Primary angioplasty, rescue angioplasty, and new devices. In: Hennekens CH, editor. Clinical Trials in Cardiovascular Disease: A Companion to Braunwald's Heart Disease. Philadelphia, PA: W.B. Saunders; 1999. p. 194.
2. Antman EM, Morrow DA. ST-segment elevation myocardial infarction: management. In: Bonow RO, Mann D, Zipes D, Libby P, editors. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. Philadelphia, PA: W.B. Saunders; 2012. p. 1111-70.
3. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;61:e78-140.
4. Muller JE. Diagnosis of myocardial infarction: historical notes from the Soviet Union and the United States. Am J Cardiol 1977;40:269-71.
5. Herrick JB. Landmark article (JAMA 1912): clinical features of sudden obstruction of the coronary arteries. By James B. Herrick. JAMA 1983;250:1757-65.
6. James TN. Homage to James B. Herrick: a contemporary look at myocardial infarction and at sickle-cell heart disease: the 32nd Annual Herrick Lecture of the Council on Clinical Cardiology of the American Heart Association. Circulation 2000;101:1874-87.
7. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD. Third universal definition of myocardial infarction. Glob Heart 2012;7:275-95.
8. Mohan JC, Narula J. New universal definition of myocardial infarction: global implications, applicability, and need for flexibility. Glob Heart 2012;7:377-80.
9. Braunwald E. The history. In: Braunwald E, Zipes DP, Libby P, editors. Heart Disease. 6th edition. Philadelphia, PA: Saunders; 2001. p. 33.
10. Braunwald E. Acute Coronary Syndromes: A Companion to Braunwald's Heart Disease. Philadelphia., PA: Saunders; 2011. p. 94-100.
11. Opie L, Gersh BJ, editors. Drugs for the Heart. 7th edition. Philadelphia, PA: Elsevier/W.B. Saunders; 2009.
12. Boersma E, Maas AC, Deckers JW, Simoons ML. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet 1996;348:771-5.
13. Gershlick AH, Banning AP, Myat A, Verheugt FW, Gersh BJ. Reperfusion therapy for STEMI: is there still a role for thrombolysis in the era of primary percutaneous coronary intervention? Lancet 2013;382:624-32.
14. Xavier D, Pais P, Devereaux PJ, et al., for the CREATE Registry Investigators. Treatment and outcomes of acute coronary syndromes in India (CREATE): a prospective analysis of registry data. Lancet 2008;371:1435-42.
15. Windecker S, Bax JJ, Myat A, Stone GW, Marber MS. Future treatment strategies in ST-segment elevation myocardial infarction. Lancet 2013;382:644-57.
16. Li J, Li X, Wang Q, et al., for the China PEACE Collaborative Group. ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data. Lancet 2014 Jun 23 [E-pub ahead of print].
17. Peng YG, Feng JJ, Guo LF, et al. Factors associated with prehospital delay in patients with ST-segment elevation acute myocardial infarction in China. Am J Emerg Med 2014;32:349-55.
18. Hand MM. Act in time to heart attack signs: update on the National Heart Attack Alert Program's campaign to reduce patient delay. Crit Pathw Cardiol 2004;3:128-33.
19. Alexander T, Mehta S, Mullasari A, Nallamothu BK. Systems of care for ST-elevation myocardial infarction in India. Heart 2012;98:15-7.
20. Alexander T, Victor SM, Mullasari AS, et al., for the TN-STEMI Programme Investigators. Protocol for a prospective, controlled study of assertive and timely reperfusion for patients with ST-segment elevation myocardial infarction in Tamil Nadu: the TN-STEMI programme. BMJ Open 2013;3:e003850.
21. Wiviott SD, Morrow DA, Frederick PD, et al. Performance of the thrombolysis in myocardial infarction risk index in the National Registry of Myocardial Infarction-3 and -4: a simple index that predicts mortality in ST-segment elevation myocardial infarction. J Am Coll Cardiol 2004;44:783-9.
22. Tricomi AJ, Magid DJ, Rumsfeld JS, et al., for the EDQMI Study Investigators. Missed opportunities for reperfusion therapy for ST-segment elevation myocardial infarction: results of the Emergency Department Quality in Myocardial Infarction (EDQMI) study. Am Heart J 2008;155:471-7.
23. Ranasinghe I, Turnbull F, Tonkin A, Clark RA, Coffee N, Brieger D. Comparative effectiveness of population interventions to improve access to reperfusion for ST-segment-elevation myocardial infarction in Australia. Circ Cardiovasc Qual Outcomes 2012;5:429-36.
24. Chakrabarti AK, Gibson CM, Pinto DS. Optimal selection of STEMI treatment strategies in the current era: benefit of transferring STEMI patients for PCI compared with administration of onsite fibrinolytic therapy. Curr Opin Cardiol 2012;27:651-4.
25. Pinto DS, Kirtane AJ, Nallamothu BK, et al. Hospital delays in reperfusion for ST-elevation myocardial infarction: implications when selecting a reperfusion strategy. Circulation 2006;114:2019-25.
26. Terkelsen CJ, Sorensen JT, Maeng M, et al. System delay and mortality among patients with STEMI treated with primary percutaneous coronary intervention. JAMA 2010;304:763-71.
27. Nielsen PH, Terkelsen CJ, Nielsen TT, et al., for the DANAMI-2 Investigators. System delay and timing of intervention in acute myocardial infarction (from the Danish Acute Myocardial Infarction-2 [DANAMI-2] trial). Am J Cardiol 2011;108:776-81.
28. Bonnefoy E, Steg PG, Boutitie F, et al., for the CAPTIM Investigators. Comparison of primary angioplasty and pre-hospital fibrinolysis in acute myocardial infarction (CAPTIM) trial: a 5-year follow-up. Eur Heart J 2009;30:1598-606.
29. Bonnefoy E, Lapostolle F, Leizorovicz A, et al., for the Comparison of Angioplasty and Prehospital Thrombolysis in Acute Myocardial Infarction Study Group. Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study. Lancet 2002;360:825-9.
30. Mensah GA, Hand MM, Antman EM, Ryan TJ Jr, Schriever R, Smith SC Jr. Development of systems of care for ST-elevation myocardial infarction patients: the patient and public perspective. Circulation 2007;116:e33-8.
31. Ting HH, Bradley EH, Wang Y, et al. Delay in presentation and reperfusion therapy in ST-elevation myocardial infarction. Am J Med 2008;121:316-23.
32. Moser DK, Kimble LP, Alberts MJ, et al. Reducing delay in seeking treatment by patients with acute coronary syndrome and stroke: a scientific statement from the American Heart Association Council on Cardiovascular Nursing and Stroke Council. Circulation 2006;114:168-82.
33. Gershlick AH, Stephens-Lloyd A, Hughes S, et al., for the REACT Trial Investigators. Rescue angioplasty after failed thrombolytic therapy for acute myocardial infarction. N Engl J Med 2005;353:2758-68.
34. Fernandez-Aviles F, Alonso JJ, Castro-Beiras A, et al., for the GRACIA Group. Routine invasive strategy within 24 hours of thrombolysis versus ischaemia-guided conservative approach for acute myocardial infarction with ST-segment elevation (GRACIA-1): a randomised controlled trial. Lancet 2004;364:1045-53.
35. Killip T 3rd, Kimball JT. Treatment of myocardial infarction in a coronary care unit: a two year experience with 250 patients. Am J Cardiol 1967;20:457-64.
36. DeGeare VS, Boura JA, Grines LL, O'Neill WW, Grines CL. Predictive value of the Killip classification in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol 2001;87:1035-8.
37. de Araujo Gonc¸alves P, Ferreira J, Aguiar C, Seabra-Gomes R. TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS. Eur Heart J 2005;26:865-72.
38. Morrow DA, Antman EM, Giugliano RP, et al. A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: an InTIME II substudy. Lancet 2001;358:1571-5.
39. Riordan J, Brady WJ. Textbook of Critical Care. Philadelphia, PA: Saunders; 2011. p. 538-47.
40. Goldberger AL. Clinical Electrocardiography: A Simplified Approach. Philadelphia, PA: Saunders; 2013. p. 65-81.
41. Terkelsen CJ. Cardiology. New York, NY: Elsevier; 2010. p. 361-5.
42. Crawford MH. Cardiology. New York, NY: Elsevier; 2010. p. 449-60.
43. White HD, Chew DP. Acute myocardial infarction. Lancet 2008;372:570-84.
44. Geft IL, Shah PK, Rodriguez L, et al. ST elevations in leads V1 to V5 may be caused by right coronary occlusion and acute right ventricular infarction. Am J Cardiol 1984;53:991-6.
45. Shah PK, Swan HJC. Predominant right ventricular dysfunction in acute myocardial infarction. Med Rounds 1984;3:6.
46. Cercek B, Shah PK. Cardiology. New York, NY: Elsevier; 2010. p. 403-20.
47. Mani AJ, Brown DL. Cardiac Intensive Care. Philadelphia, PA: Saunders; 2010. p. 225-32.
48. Lopez-Sendon J, Coma-Canella I, Alcasena S, Seoane J, Gamallo C. Electrocardiographic findings in acute right ventricular infarction: sensitivity and specificity of electrocardiographic alterations in right precordial leads V4R, V3R, V1, V2, and V3. J Am Coll Cardiol 1985;6:1273-9.
49. Andersen HR, Falk E, Nielsen D. Right ventricular infarction: diagnostic accuracy of electrocardiographic right chest leads V3R to V7R investigated prospectively in 43 consecutive fatal cases from a coronary care unit. Br Heart J 1989;61:514-20.
50. Goldberger AL. Myocardial Infarction: Electrocardiographic Differential Diagnosis. 4th edition. St. Louis, MO: Mosby; 1991.
51. Sugiura T, Iwasaka T, Takehana K, Nagahama Y, Hasegawa T, Inada M. Precordial ST segment depression in patients with Q wave inferior myocardial infarction: role of infarction-associated pericarditis. Am Heart J 1993;125:672-5.
52. Berry C, Zalewski A, Kovach R, Savage M, Goldberg S. Surface electrocardiogram in the detection of transmural myocardial ischemia during coronary artery occlusion. Am J Cardiol 1989;63:21-6.
53. Huey BL, Beller GA, Kaiser DL, Gibson RS. A comprehensive analysis of myocardial infarction due to left circumflex artery occlusion: comparison with infarction due to right coronary artery and left anterior descending artery occlusion. J Am Coll Cardiol 1988;12:1156-66.
54. Bush HS, Ferguson JJ 3rd, Angelini P, Willerson JT. Twelve-lead electrocardiographic evaluation of ischemia during percutaneous transluminal coronary angioplasty and its correlation with acute reocclusion. Am Heart J 1991;121:1591-9.
55. Matetzky S, Freimark D, Feinberg MS, et al. Acute myocardial infarction with isolated ST-segment elevation in posterior chest leads V7e9: "hidden " ST-segment elevations revealing acute posterior infarction. J Am Coll Cardiol 1999;34:748-53.
56. Gorgels AP, Engelen DJ, Wellens HJ. Lead aVR, a mostly ignored but very valuable lead in clinical electrocardiography. J Am Coll Cardiol 2001;38:1355-6.
57. Hutchison SJ, Rudakewich G. Complications of Myocardial Infarction: Clinical Diagnostic Imaging Atlas. 1st edition. Philadelphia, PA: Saunders; 2009. p. 1-26.
58. Yamaji H, Iwasaki K, Kusachi S, et al. Prediction of acute left main coronary artery obstruction by 12-lead electrocardiography: ST segment elevation in lead aVR with less ST segment elevation in lead V(1). J Am Coll Cardiol 2001;38:1348-54.
59. Engelen DJ, Gorgels AP, Cheriex EC, et al. Value of the electrocardiogram in localizing the occlusion site in the left anterior descending coronary artery in acute anterior myocardial infarction. J Am Coll Cardiol 1999;34:389-95.
60. Wong CK, Gao W, Stewart RA, et al., for the HERO-2 Investigators. The prognostic meaning of the full spectrum of aVR ST-segment changes in acute myocardial infarction. Eur Heart J 2012;33:384-92.
61. Donahue B, Chan SB. Bhandarkar Steve. Rapid progression of Wellens syndrome in the emergency department. J Emerg Med 2012;43:667-70.
62. Brown D. Emergency Medicine. Philadelphia, PA: Saunders; 2013. p. 452-468.e1.
63. Tung R, Zimetbaum P. Use of electrocardiogram in acute myocardial infarction. In: Jeremias A, Brown DL, editors. Cardiac Intensive Care. 2nd edition. Philadelphia, PA: Saunders; 2010:106-9.
64. Cai Q, Mehta N, Sgarbossa EB, et al. The left bundle-branch block puzzle in the 2013 ST-elevation myocardial infarction guideline: from falsely declaring emergency to denying reperfusion in a high-risk population. Are the Sgarbossa Criteria ready for prime time? Am Heart J 2013;166:409-13.
65. Wellens HJJ, Kulbertus HE. What's New in Electrocardiography. Boston, MA: M. Nijhoff Publishers; 1981.
66. Sgarbossa EB, Pinski SL, Barbagelata A, et al., for the GUSTO-1 Investigators. Electrocardiographic diagnosis of evolving acute myocardial infarction in the presence of left bundle-branch block. N Engl J Med 1996;334:481-7.
67. Pollak P, Brady W. Electrocardiographic patterns mimicking ST segment elevation myocardial infarction. Cardiol Clin 2012;30:601-15.
68. Kumar V, Venkataraman R, Aljaroudi W, et al. Implications of left bundle branch block in patient treatment. Am J Cardiol 2013;111:291-300.
69. Brady WJ, Lentz B, Barlotta K, Harrigan RA, Chan T. ECG patterns confounding the ECG diagnosis of acute coronary syndrome: left bundle branch block, right ventricular paced rhythms, and left ventricular hypertrophy. Emerg Med Clin North Am 2005;23:999-1025.
70. Patanè S. Paced patient and acute myocardial infarction. Int J Cardiol 2012;161:e16-7.
71. Krishnaswamy A, Lincoff AM, Menon V. Magnitude and consequences of missing the acute infarct-related circumflex artery. Am Heart J 2009;158:706-12.
72. From AM, Best PJ, Lennon RJ, Rihal CS, Prasad A. Acute myocardial infarction due to left circumflex artery occlusion and significance of ST-segment elevation. Am J Cardiol 2010;106:1081-5.
73. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). J Am Coll Cardiol 2004;44:E1-211.
74. Aldous SJ. Cardiac biomarkers in acute myocardial infarction. Int J Cardiol 2013;164:282-94.
75. Jaffe AS, Babuin L, Apple FS. Biomarkers in acute cardiac disease: the present and the future. J Am Coll Cardiol 2006;48:1-11.
76. Christenson E, Christenson RH. The role of cardiac biomarkers in the diagnosis and management of patients presenting with suspected acute coronary syndrome. Ann Lab Med 2013;33:309-18.
77. Dolci A, Panteghini M. The exciting story of cardiac biomarkers: from retrospective detection to gold diagnostic standard for acute myocardial infarction and more. Clin Chim Acta 2006;369:179-87.
78. Hypertension and coronary heart disease: classification and criteria for epidemiological studies. World Health Organ Tech Rep Ser 1959;58:1-28.
79. Ladenson JH. A personal history of markers of myocyte injury [myocardial infarction]. Clin Chim Acta 2007;381:3-8.
80. Ruzich RS. Cardiac enzymes: how to use serial determinations to confirm acute myocardial infarction. Postgrad Med 1992;92:85-9, 92.
81. Lee TH, Goldman L. Serum enzyme assays in the diagnosis of acute myocardial infarction: recommendations based on a quantitative analysis. Ann Intern Med 1986;105:221-33.
82. Wu AH, Valdes R Jr, Apple FS, et al. Cardiac troponin-T immunoassay for diagnosis of acute myocardial infarction. Clin Chem 1994;40:900-7.
83. Lott JA, Stang JM. Serum enzymes and isoenzymes in the diagnosis and differential diagnosis of myocardial ischemia and necrosis. Clin Chem 1980;26:1241-50.
84. Apple FS, Collinson PO. IFCC Task Force on Clinical Application of Cardiac Biomarkers. Analytical characteristics of high-sensitivity cardiac troponin assays. Clin Chem 2012;58:54-61.
85. Bessman SP, Carpenter CL. The creatine-creatine phosphate energy shuttle. Annu Rev Biochem 1985;54:831-62.
86. Zimmerman J, Fromm R, Meyer D, et al. Diagnostic marker cooperative study for the diagnosis of myocardial infarction. Circulation 1999;99:1671-7.
87. Tsung JS, Tsung SS. Creatine kinase isoenzymes in extracts of various human skeletal muscles. Clin Chem 1986;32:1568-70.
88. Adams JE 3rd, Abendschein DR, Jaffe AS. Biochemical markers of myocardial injury: Is MB creatine kinase the choice for the 1990s? Circulation 1993;88:750-63.
89. Mair J, Puschendorf B, Michel G. Clinical significance of cardiac contractile proteins for the diagnosis of myocardial injury. Adv Clin Chem 1994;31:63-98.
90. Thygesen K, Alpert JS, White HD. Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. J Am Coll Cardiol 2007;50:2173-95.
91. Gerhardt W, Katus H, Ravkilde J, et al. S-troponin T in suspected ischemic myocardial injury compared with mass and catalytic concentrations of S-creatine kinase isoenzyme MB. Clin Chem 1991;37:1405-11.
92. Wu AH, Jaffe AS. The clinical need for high-sensitivity cardiac troponin assays for acute coronary syndromes and the role for serial testing. Am Heart J 2008;155:208-14.
93. Diaz A, Ducharme A, Tardif JC. In: Théroux P, editor. Acute Coronary Syndromes: A Companion to Braunwald's Heart Disease. 2nd edition. Philadelphia, PA: Saunders; 2011. p. 129-47.
94. Khan R, Ly HQ. Transradial percutaneous coronary interventions in acute coronary syndrome. Am J Cardiol 2014;114:160-8.
95. Jernberg T, Johanson P, Held C, et al., for the SWEDEHEART/RIKSHIA. Association between adoption of evidence-based treatment and survival for patients with ST-elevation myocardial infarction. JAMA 2011;305:1677-84.
96. McNulty PH, King N, Scott S, et al. Effects of supplemental oxygen administration on coronary blood flow in patients undergoing cardiac catheterization. Am J Physiol Heart Circ Physiol 2005;288:H1057-62.
97. ISIS-2 Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349-60.
98. Chung SC, Gedeborg R, Nicholas O, et al. Acute myocardial infarction: a comparison of short-term survival in national outcome registries in Sweden and the UK. Lancet 2014;383:1305-12.
99. Boersma E, for the Primary Coronary Angioplasty vs. Thrombolysis Group. Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients. Eur Heart J 2006;27:779-88.
100. Reimer KA, Jennings RB. The " wavefront phenomenon " of myocardial ischemic cell death. II. Transmural progression of necrosis within the framework of ischemic bed size (myocardium at risk) and collateral flow. Lab Invest 1979;40:633-44.
101. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;1:397-402.
102. Franzosi MG, Santoro E, De Vita C, et al., for the GISSI Investigators. Ten-year follow-up of the first megatrial testing thrombolytic therapy in patients with acute myocardial infarction: results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto-1 study. Circulation 1998;98:2659-65.
103. Langer A, Goodman SG, Topol EJ, et al., for the LATE Study Investigators. Late assessment of thrombolytic efficacy (LATE) study: prognosis in patients with non-Q wave myocardial infarction. J Am Coll Cardiol 1996;27:1327-32.
104. Opie LH, Gersh BJ. Drugs for the Heart. 8th edition. Philadelphia, PA: Elsevier; 2013.
105. De Luca G, Suryapranata H, Ottervanger JP, Antman EM. Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts. Circulation 2004;109:1223-5.
106. Gibson CM, Cannon CP, Piana RN, et al. Angiographic predictors of reocclusion after thrombolysis: results from the Thrombolysis In Myocardial Infarction (TIMI) 4 trial. J Am Coll Cardiol 1995;25:582-9.
107. Fath-Ordoubadi F, Huehns TY, Al-Mohammad A, Beatt KJ. Significance of the Thrombolysis in Myocardial Infarction scoring system in assessing infarct-related artery reperfusion and mortality rates after acute myocardial infarction. Am Heart J 1997;134:62-8.
108. Harnek J, Nilsson J, Friberg O, et al. The 2011 outcome from the Swedish Health Care Registry on Heart Disease (SWEDEHEART). Scand Cardiovasc J 2013;47(Suppl 62):1-10.
109. Hochman JS, Lamas GA, Buller CE, et al., for the Occluded Artery Trial Investigators. Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med 2006;355:2395-407.
110. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003;361:13-20.
111. Grines CL, Marsalese DL, Brodie B, et al., for the PAMI-II Investigators. Safety and cost-effectiveness of early discharge after primary angioplasty in low risk patients with acute myocardial infarction. J Am Coll Cardiol 1998;31:967-72.
112. Grines CL, Browne KF, Marco J, et al., for the PAMI Study Group. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1993;328:673-9.
113. Aversano T, Aversano LT, Passamani E, et al., for the Atlantic Cardiovascular Patient Outcomes Research Team. Thrombolytic therapy vs primary percutaneous coronary intervention for myocardial infarction in patients presenting to hospitals without on-site cardiac surgery: a randomized controlled trial. JAMA 2002;287:1943-51.
114. Gersh BJ, Antman EM. Selection of the optimal reperfusion strategy for STEMI: does time matter? Eur Heart J 2006;27:761-3.
115. Wijeysundera HC, Vijayaraghavan R, Nallamothu BK, et al. Rescue angioplasty or repeat fibrinolysis after failed fibrinolytic therapy for ST-segment myocardial infarction: a meta-analysis of randomized trials. J Am Coll Cardiol 2007;49:422-30.
116. Gogo PB, Dauerman HL, Sobel BE. Cardiac Intensive Care. Philadelphia, PA: Saunders; 2010. p. 110-44.
117. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994;343:311-22.
118. Van de Werf FJ, Topol EJ, Sobel BE. The impact of fibrinolytic therapy for ST-segment-elevation acute myocardial infarction. J Thromb Haemost 2009;7:14-20.
119. Nallamothu BK, Bates ER. Percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction: is timing (almost) everything? Am J Cardiol 2003;92:824-6.
120. Steg PG, Bonnefoy E, Chabaud S, et al., for the CAPTIM Investigators. Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial. Circulation 2003;108:2851-6.
121. Weaver WD, Cerqueira M, Hallstrom AP, et al. Prehospital-initiated vs hospital-initiated thrombolytic therapy: the Myocardial Infarction Triage and Intervention Trial. JAMA 1993;270:1211-6.
122. Dalal JJ, Alexander T, Banerjee PS, et al., for participating STEMI experts. 2103 consensus statement for early reperfusion and pharmacoinvasive approach in patients presenting with chest pain diagnosed as STEMI in an Indian setting. J Assoc Physicians India 2014;62:473-83.
123. Simoons ML, Maggioni AP, Knatterud G, et al. Individual risk assessment for intracranial haemorrhage during thrombolytic therapy. Lancet 1993;342:1523-8.
124. Brass LM, Lichtman JH, Wang Y, Gurwitz JH, Radford MJ, Krumholz HM. Intracranial hemorrhage associated with thrombolytic therapy for elderly patients with acute myocardial infarction: results from the Cooperative Cardiovascular Project. Stroke 2000;31:1802.
125. Sloan MA, Giuglano RP, Thompson SL, et al. Prediction of intracranial hemorrhage in the InTIME-II trial. J Am Coll Cardiol 2001;37(Suppl A):327A.
126. Eagle KA, Goodman SG, Avezum A, et al., for the GRACE Investigators. Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE). Lancet 2002;359:373-7.
127. GUSTO IIb Investigators. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1997;336:1621-8.
128. GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993;329:1615-22.
129. Anderson JL, Karagounis LA, Becker LC, Sorensen SG, Menlove RL. TIMI perfusion grade 3 but not grade 2 results in improved outcome after thrombolysis for myocardial infarction: ventriculographic, enzymatic, and electrocardiographic evidence from the TEAM-3 Study. Circulation 1993;87:1829-39.
130. Gibson CM, Karha J, Murphy SA, et al., for the TIMI Study Group. Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis in Myocardial Infarction trials. J Am Coll Cardiol 2003;42:7-16.
131. Armstrong PW, Gershlick AH, Goldstein P, et al., for the STREAM Investigative Team. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med 2013;368:1379-87.
132. Widimský P, Budesinský T, Vorác D, et al., for the PRAGUE Study Group Investigators. Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction: final results of the randomized national multicentre trial - PRAGUE-2. Eur Heart J 2003;24:94-104.
133. Victor SM, Subban V, Alexander T, et al. A prospective, observational, multicentre study comparing tenecteplase facilitated PCI versus primary PCI in Indian patients with STEMI (STEPP-AMI). Open Heart 2014;1:e000133.
134. Curzen N, Gurbel PA, Myat A, Bhatt DL, Redwood SR. What is the optimum adjunctive reperfusion strategy for primary percutaneous coronary intervention? Lancet 2013;382:633-43.
135. Mehta SR, Yusuf S, Peters RJ, et al., for the CURE Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-33.
136. Chen ZM, Jiang LX, Chen YP, et al., for the COMMIT Collaborative Group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366:1607-21.
137. Sabatine MS, Cannon CP, Gibson CM, et al., for the CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005;352:1179-89.
138. Chen ZM, Pan HC, Chen YP, et al., for the COMMIT Collaborative Group. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366:1622-32.
139. Wallentin L, Becker RC, Budaj A, et al., for the PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57.
140. Morrow DA. Heparin and low-molecular weight heparin. In: Manson JE, Buring JE, Ridker PM, Gaziano JM, editors. Clinical Trials in Heart Disease: A Companion in Braunwald's Disease. Philadelphia, PA: Elsevier/Saunders; 2004. p. 45-65.
141. Singh S, Bahekar A, Molnar J, Khosla S, Arora R. Adjunctive low molecular weight heparin during fibrinolytic therapy in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized control trials. Clin Cardiol 2009;32:358-64.
142. Bittl JAWH, Antman EM. Direct thrombin inhibitors. In: Manson JE, Buring JE, Ridker PM, Gaziano JM, editors. Clinical Trials in Heart Disease: A Companion to Braunwald's Heart Disease. Philadelphia, PA: Elsevier/Saunders; 2004. p. 83-96.
143. Stone GW, Witzenbichler B, Guagliumi G, et al., for the HORIZONSAMI Trial Investigators. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008;358:2218-30.
144. Shahzad A, Kemp I, Mars C, et al., for the HEAT-PPCI Trial Investigators. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial. Lancet 2014;384:1849-58.
145. Gornik H, O'Gara PT. Adjunctive medical therapy. In: Manson JE, Buring JE, Ridker PM, Gaziano JM, editors. Clinical Trials in Heart Disease: A Companion to Braunwald's Heart Disease. Philadelphia, PA: Elsevier/Saunders; 2004. p. 114.
146. Baigent C, Keech A, Kearney PM, et al., for the CTT Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.
147. Hochman JS, Buller CE, Sleeper LA, et al. Cardiogenic shock complicating acute myocardial infarction-etiologies, management and outcome: a report from the SHOCK Trial Registry. Should we emergently revascularize Occluded Coronaries for cardiogenic shocK? J Am Coll Cardiol 2000;36(Suppl A):1063-70.
148. Menon V, White H, LeJemtel T, Webb JG, Sleeper LA, Hochman JS. The clinical profile of patients with suspected cardiogenic shock due to predominant left ventricular failure: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries in cardiogenic shocK? J Am Coll Cardiol 2000;36(Suppl A):1071-6.
149. Forrester JS, Diamond GA, Swan HJ. Correlative classification of clinical and hemodynamic function after acute myocardial infarction. Am J Cardiol 1977;39:137-45.
150. Lorrell B, Leinbach RC, Pohost GM, et al. Right ventricular infarction: clinical diagnosis and differentiation from cardiac tamponade and pericardial constriction. Am J Cardiol 1979;43:465-71.
151. Schoen FJ. The heart. In: Kumar V, Abbas AK, Fausto N, editors. Robbins & Cotran Pathologic Basis of Disease. 8th edition. Philadelphia, PA: Saunders; 2010. p. 529-87.
152. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines on the management of patients with acute myocardial infarction). J Am Coll Cardiol 2004;44:671-719.
153. Fonarow GC, Gawlinski A, Moughrabi S, Tillisch JH. Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). Am J Cardiol 2001;87:819-22.
154. Hass EE, Smith SC. Cardiology. New York, NY: Elsevier; 2010. p. 427-47.